ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2657

Brain Gray and White Matter Volume Losses and Their Associations with Glucocorticoid Use in Patients with Newly Diagnosed Systemic Lupus Erythematosus (SLE) – a Prospective MR Study

Anselm Mak1, Roger CM Ho2, Hanying Tng3 and Juan Zhou3, 1Medicine, National University of Singapore, Singapore, Singapore, 2Psychological Medicine, National University of Singapore, Singapore, Singapore, 3Center for Cognitive Neuroscience, Duke-NUS Graduate Medical School, Singapore, Singapore

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: magnetic resonance imaging (MRI) and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women's Health, Cardiovascular and CNS

Session Type: Abstract Submissions (ACR)

Background/Purpose

Data suggest that cerebral atrophy occurs in patients with SLE as early as within 9 months after disease onset. We aimed to address (1) if cerebral atrophy occurs even earlier after disease onset and (2) if glucocorticoid use early in the course of SLE would positively impact the brain gray matter (GMV) and white matter volumes (WMV).

Methods

Whole brain analyses of T1-weighted magnetic resonance (MR) images (1.5-T Siemen scanner) obtained ≤ 3 months of diagnosis and subsequently after sufficient disease control (SLEDAI<4) from 14 patients with new onset SLE (1997 ACR classification criteria) without clinically overt neuropsychiatric symptoms, traditional cardiovascular risk factors and antiphospholipid antibodies were performed. MR images of 14 demographically and intelligent-quotient matched healthy controls (HC) were used for comparison. An optimized voxel-based morphometry protocol was used to analyse the images. With thresholding at p<0.01 family-wise error (FWE) corrected, GMV and WMV between patients at diagnosis and HC were compared by 2-sample t-tests on 2-subject level probabilistic maps, while changes of GMV and WMV within the SLE group at diagnosis and after achieving sufficient disease control were compared by paired t-tests. Cumulative glucocorticoid doses were correlated with the changes of GMV and WMV of the regions of interest (ROI) within the SLE group.  

Results

The mean±SD age of the patients at diagnosis and HC were 39.38±13.9 and 34.07±14.4 years respectively. The mean±SD SLEDAI and daily prednisolone dose were 9.93±5.7 and 15.32±18.4mg respectively. The mean±SD interval between diagnosis and the first MR scan was 36.86±35.5 days. Second MR scans in lupus patients were performed after a mean±SD of 504.92+267.0 days of treatment, with significant improvement of mean±SD SLEDAI and daily prednisolone dose to 2.64±1.4 (p<0.001) and 3.82±3.5mg (p=0.023) respectively. The mean±SD cumulative prednisolone was 1.76±2.10gm.  Demonstrated in the first scans, lupus patients had significant GMV losses in both middle cingulate cortices and middle frontal gyrus, right rolandic operculum and the right supplementary motor area (lower panel of figure), and significant WMV losses in both superior longitudinal fasciculus, corticospinal tract, cingulum cingulate gyrus and inferior fronto-occipital fasciculus (upper panel of figure) as compared with HC. On ROI analyses, cumulative glucocorticoid dose was significantly correlated with improvement of brain volumes in the left inferior temporal gyrus, left cerebellum, and both anterior thalamic radiation in the SLE patients (all p<0.05).

Conclusion

In SLE patients, significant gray and white matter losses occurred as early as within a mean of 36.9 days of diagnosis. Glucocorticoid use early in the disease course improved GMV and WMV in certain areas, suggesting the potential benefit of glucocorticoids in brain plasticity and connectivity in early SLE.    


Disclosure:

A. Mak,
None;

R. C. Ho,
None;

H. Tng,
None;

J. Zhou,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/brain-gray-and-white-matter-volume-losses-and-their-associations-with-glucocorticoid-use-in-patients-with-newly-diagnosed-systemic-lupus-erythematosus-sle-a-prospective-mr-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology